Investorideas.com newswire, defense and security sector

Monday, July 23, 2012

Homeland Defense and Security Q&A Interview with PositiveID (OTCBB: PSID): How the M-BAND System Biothreat Detection is in the Running for BioWatch

New York, NY - July 23, 2012 - (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Mr. William J. Caragol, Chairman and Chief Executive Officer of PositiveID Corporation (OTCBB: PSID) discussing its M-BAND System for biothreat detection.

Q: Investorideas.com
Can you briefly explain to new investors how the M-BAND System works and how it can be deployed in the BioWatch Generation 3 program?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Our Microfluidics-based Bioagent Networked Detector, called M-BAND, was developed under contract for the Department of Homeland Security (DHS), and is an early warning system designed to detect the intentional release of aerosolized biological agents. It runs autonomously for up to 30 days between service cycles, continuously analyzing air samples, typically in high-traffic areas, for the detection of bacteria, viruses, and toxins with results in as little as three hours. Results from individual M-BAND instruments are reported via a secure wireless network in real time to give an accurate and up to date status for instruments in the field in aggregate. M-BAND was designed with a high level of operational flexibility, and can be remotely set to detect for DNA-based pathogens alone, with or without either RNA-based organisms or toxins, or for all three types of pathogens simultaneously at remotely programmable intervals.
Q: Investorideas.com
We understand the Department of Homeland Security wants to open bidding before October for Generation 3 of the BioWatch program, now estimated at $5.7 Billion. Where is PSID in the process?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We are currently awaiting the final RFP from the Department of Homeland Security, which is expected to be released later this year. In the meantime, we have made significant progress in our internal testing of M-BAND, which detects five organisms on the Centers for Disease Control Select Agents List, which is a requirement for BioWatch. Our system is fully functional and, we believe, one of the only technologies capable of addressing the requirements of the BioWatch procurement. We are preparing for potential additional testing of our system as well.
Q: Investorideas.com
The other company bidding for the BioWatch program is Northrop Grumman (NYSE:NOC); is this competitive against your technology or more synergistic?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We believe the M-BAND instrument offers a number of advantages over similar products, including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation. M-BAND has been designed and field tested (both indoors and outdoors) to operate continuously for 30 days unattended between scheduled services, which we believe to be higher than competing technologies. It also operates using industry gold-standard TaqMan® PCR (polymerase chain reaction) chemistry.
Q: Investorideas.com
Your Company was recently featured in a Bloomberg Businessweek.com article discussing BioWatch; did that lend a new level of credibility for your company being a small OTC listed stock?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We believe articles like the one published in Bloomberg Businessweek shed light on the need for BioWatch Generation 3, and also highlight and validate our technology and our company. Many people may not have been previously aware of PositiveID or M-BAND, so it was very significant for our company and technology to be featured alongside the likes of Northrop Grumman. We have already received additional inquiries and interest from large corporations around the world including for possible partnership opportunities, as well as increased investor interest.
Q: Investorideas.com
Are you targeting any other markets forthe M-BAND System globally?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Unfortunately, terrorism is not limited to the United States, so M-BAND could be deployed in any location around the globe. In fact, the system has been field tested in London.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.www.PositiveIDCorp.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com: 800 665 0411
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Investorideas.com newswire